TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04243304

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 11C-UCB-J PET-CT
Description: Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 11C-UCB-J PET-CT
Description: Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 18F-PE2I PET-MR
Description: Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-PE2I PET-MR
Description: Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
Study: NCT02462369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Study: NCT03547479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VDOT
Description: In VDOT, reminder notifications are sent x minutes prior to the scheduled pill time, and continue every y minutes until the user sends a video of themselves taking their pill via the app. Instructions will be provided in Khmer. The web system has an administrator component whereby a healthcare provider can log in via the Internet to monitor and validate all the videos received that day, and reasons for non-submission.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VDOT + mobile money
Description: The VDOT intervention above will be paired with financial incentives in the form of mobile payments in one of the experimental arms.
Study: NCT02506257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.04% PHMB
Description: 0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.06% PHMB
Description: 0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.08% PHMB
Description: 0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PHMB Vehicle
Description: PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Study: NCT03663842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy treatment
Description: All patients underwent the same techniques, and there was no modification of the intervention protocol during the study: (1) Myofascial release technique - piriformis muscle and biceps femoral muscle; (2) Hip joint mobilization; (3) Cross-fiber friction over the sacroiliac joints; (4) Neural mobilization to improve sciatic nerve excursion.
Study: NCT03760419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: For enrolled subjects assigned to the decision support arm, providers will receive antibiotic recommendations in accordance with the 2011 PIDS/IDSA guideline, tailored to site of care and illness severity. The tool will offer treatment recommendations only and will not proscribe a specific treatment plan.
Study: NCT01924767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 Placebo
Description: po taken fasting with 240 mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: po taken fasting with 240 mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 Placebo
Description: po taken fasting with 240 mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: po taken fasting with 240 mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 Placebo
Description: po taken fasting with 240 mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 Placebo
Description: po taken fasting with 240 mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: po taken fasting with 240 mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: po taken fasting with 240 mL water
Study: NCT01442935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m² over 120 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m² over 120 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: 400mg/m² over 120 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: 400mg/m² over 120 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 400mg/m² over 120 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180mg/m² over 90 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5mg/kg over 90 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5mg/kg over 90 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg over 90 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 500mg/m² over 90 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 500mg/m² over 90 mn every 2 weeks up to progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500mg/m² over 90 mn every 2 weeks up to progression or toxicity
Study: NCT03522558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Medical Nutrition Therapy
Description: Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
Study: NCT01563354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: 60 mg was administered as an intra muscular depot injection once every 28 days starting at Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg tables administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR and Everolimus Combination
Description: Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
Study: NCT01035658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
Study: NCT03204396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])
Description: Application of 0.5 ml normal saline (0.9% sodium chloride \[0.9% NaCl\]) once weekly for 12 weeks
Study: NCT01689272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Transplantation from alive relative donor
Description: Donor kidney sampling, preservation, transport and transplantation
Study: NCT04864925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Total Clean Mint
Description: 2 minutes of whole mouth toothbrushing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tom's Botanically Bright Peppermint
Description: 2 minutes of whole mouth toothbrushing
Study: NCT01082809

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Sunitinib
Description: Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
Study: NCT03951649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Occipital Nerve Block
Description: This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Occipital Nerve Block
Description: This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
Study: NCT04116515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Xbox / active video games
Description: The investigators would expect children to play active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Xbox / active video games
Description: The investigators would expect children to play active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
Study: NCT02621879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Gluteal Advancement Flap
Description: Dissection of both gluteus maximus muscles from their origin in the sacrum, advancement of both muscles is conducted to the midline after creating release incisions in their fascia.
Study: NCT02000713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Exam
Description: Brief neurological exam will be performed.
Study: NCT03396250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and diphenhydramine hydrochloride soft capsules
Description: Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and diphenhydramine hydrochloride soft capsules
Description: Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)
Description: Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)
Description: Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
Study: NCT04116515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animated cartoon narratives
Description: The investigators would expect the animated cartoon narratives to motivate children to play more active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard clinical care
Description: Each clinic will provide standard clinical care to the participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard clinical care
Description: Each clinic will provide standard clinical care to the participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical care
Description: Each clinic will provide standard clinical care to the participants.
Study: NCT01282346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOLX Gold Shunt
Description: Single use implant
Study: NCT03165071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-132577
Description: Capsule
Study: NCT02272959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention bias modification treatment (ABMT)
Description: Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Condition
Description: Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
Study: NCT03387319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Racialized Stressful Event Recall
Description: Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, race-related event.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Racialized Stressful Event Recall
Description: Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, event unrelated to race.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses.
Study: NCT04514055

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: De-epithelialized connective tissue graft wall
Description: A de-epithelialized free gingival connective tissue graft will be used to treat Cairo's recession type 2 and type 3 associated with inta-bony defects
Study: NCT03093272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: a GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
Study: NCT03752398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb®23104
Description: Monoclonal bispecific antibody
Study: NCT04372394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: Surufatinib: 300 mg as a single dose on Days 1 and 8 with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: Surufatinib: 300 mg as a single dose on Days 1 and 8 with or without food
Study: NCT02212054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conservative
Description: anal dilatation; colonic lavage; oral probiotic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative
Description: one stage pull through radical colectomy
Study: NCT01387334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training Program With Rubber Bands
Description: Resistive exercise consist of 5-min warm up, at least 30 min resistive exercise using rubber band as recommendation (8-12 times per set, at least 3 sets per day and at least 3 days per week) and 5-min cool down
Study: NCT03885817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training and nutritional guide
Description: 30 minutes of a combination of sensorimotor- and strength training guided by a physical therapist twice a week. In addition 90 minutes a week of moderate intensity aerobic training or 45 minutes a week of high intensity aerobic training. Once a month the participants will fill out the form, PG-SGA SF, and he or she will be referred to a nutritionist if the score is 2 or higher. The intervention period lasts as long as the participants receives adjuvant chemotherapy, i.e. 3 - 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard follow-up care
Description: standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up care
Description: standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.
Study: NCT03851549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New BGMS (US)
Description: New blood glucose monitoring system / In vitro diagnostic device (IVDD)
Study: NCT00487305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells
Description: Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
Study: NCT04645550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.